Company news
Mdxhealth Sa (NASDAQ:MDXH) news
Mdxhealth Sa news releases on 6ix. Latest, Aug 13, 2026: Mdxhealth Reports Second Quarter 2026 Financial Results
Press releases & updates
Mdxhealth Reports Second Quarter 2026 Financial Results
August 13, 2026
Mdxhealth to Release Second Quarter 2026 Financial Results on August 13
July 30, 2026
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency
July 24, 2026
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
July 2, 2026
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
June 29, 2026
Mdxhealth Reports Q1-2026 Results
May 13, 2026
Mdxhealth to Release First Quarter 2026 Financial Results on May 13
April 30, 2026
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
March 16, 2026
Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results
February 25, 2026
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
February 12, 2026
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
January 12, 2026
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
January 6, 2026
Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025
November 12, 2025
Mdxhealth to Release Third Quarter 2025 Financial Results on November 12
November 3, 2025
Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne
September 15, 2025
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
August 5, 2025
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
July 3, 2025
MDxHealth Reports Q1-2025 Results
May 14, 2025
Mdxhealth to Release First Quarter 2025 Financial Results on May 14
April 30, 2025
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results
February 26, 2025
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance
January 12, 2025
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024
November 5, 2024
MDxHealth : Underwriting Agreement Form 6 K
October 29, 2024
MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6
October 13, 2024
MDxHealth : SECURITIES PURCHASE AGREEMENT Form 6 K
September 30, 2024
MDxHealth Announces Pricing of Offering of Ordinary Shares
September 24, 2024
MDxHealth Announces Launch of Offering of Ordinary Shares
September 24, 2024
MDxHealth Reports Q2 and Half Year 2024 Results
August 20, 2024
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21
August 11, 2024
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance
July 7, 2024
Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors
July 7, 2024
MDxHealth : REGISTRATION RIGHTS AGREEMENT Form 6 K
June 20, 2024
MDxHealth : Extraordinary GENERAL MEETING Form 6 K
June 5, 2024
MDxHealth : CEO PURCHASES SHARES OF MDXHEALTH - Form 6-K
May 6, 2024
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
April 30, 2024
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
March 11, 2024
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
March 5, 2024
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
February 20, 2024
MDxHealth Announces Completion of Transition to Single Listing on Nasdaq
December 17, 2023
MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq
November 26, 2023
MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights
November 12, 2023
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023
November 7, 2023
MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation
November 5, 2023
Mdxhealth's New Share Capital Amount and New Number of Shares
October 19, 2023
MDxHealth Reports Preliminary Q3-2023 Revenues
October 8, 2023
MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting
October 1, 2023
Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer
September 25, 2023
MDxHealth Reports Q2 and Half Year 2023 Results
August 22, 2023
MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on August 23
August 9, 2023
MDxHealth Announces Results of its Extraordinary General Shareholders’ Meeting
June 29, 2023